<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00757601</url>
  </required_header>
  <id_info>
    <org_study_id>1006-002</org_study_id>
    <secondary_id>2008_549</secondary_id>
    <nct_id>NCT00757601</nct_id>
  </id_info>
  <brief_title>A Study to Test the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK1006 (MK-1006-002)(COMPLETED)</brief_title>
  <official_title>A Single Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK1006.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of
      single doses of MK1006
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AEs) On Study</measure>
    <time_frame>From the time of the run-in period prior to the first dose of study drug through the end of the poststudy period (up to 3 weeks)</time_frame>
    <description>An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the treatment, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the treatment, was also considered an adverse experience.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Treatment Due to an AE</measure>
    <time_frame>From the time of the run-in period prior to the first dose of study drug through the end of the poststudy period (up to 3 weeks)</time_frame>
    <description>An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the treatment, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the treatment, was also considered an adverse experience.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006</measure>
    <time_frame>From pre-dose to 168 hours post-dose</time_frame>
    <description>The AUC(0-∞) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose</measure>
    <time_frame>From pre-dose to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose</measure>
    <time_frame>From pre-dose to 168 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose</measure>
    <time_frame>From pre-dose to 168 hours post-dose</time_frame>
    <description>The apparent terminal half-life was defined as the time required for the plasma concentration of MK1006 to decrease 50% in the final stage of its elimination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006</measure>
    <time_frame>From pre-dose to 168 hours post-dose</time_frame>
    <description>The AUC(0-24) was estimated by determining the total area under the curve of the concentration versus time curve to 24 hours post dose.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>15 mg MK1006/Placebo/45 mg MK1006/60 mg MK1006/Placebo (Fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 15 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by placebo to MK1006 taken with food (Fed state) in Period 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/30mg MK1006/45mg MK1006/60mg MK1006/30mg MK1006 (Fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received placebo to MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15mg MK1006/30mg MK1006/Placebo/60mg MK1006/30mg MK1006 (Fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 15 mg MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15mg MK1006/30mg MK1006/45mg MK1006/Placebo/30mg MK1006 (Fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 15 mg MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60mg MK1006 / Placebo / 100mg MK1006 / 120mg MK1006 / Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 60 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by placebo to MK1006 in Period 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/ 80mg MK1006/ 100mg MK1006/ 120mg MK1006/ 140mg MK1006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received placebo to MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by 140 mg MK1006 in Period 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60mg MK1006/ 80mg MK1006/ Placebo/ 120mg MK1006/ 140mg MK1006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 60 mg MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by 140 mg MK1006 in Period 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60mg MK1006/ 80mg MK1006/ 100mg MK1006/ Placebo/ 140mg MK1006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 60 mg MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 140 mg MK1006 in Period 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>140mg MK1006 / Placebo / 200mg MK1006 / 230mg MK1006 / Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 140 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by placebo to MK1006 in Period 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/170mg MK1006/ 200mg MK1006/ 230mg MK1006/ 260mg MK1006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received placebo to MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by 260 mg MK1006 in Period 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>140mg MK1006/170mg MK1006/ Placebo/ 230mg MK1006/ 260mg MK1006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 140 mg MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by 260 mg MK1006 in Period 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>140mg MK1006/170mg MK1006/ 200mg MK1006/ Placebo/ 260mg MK1006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 140 mg MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 260 mg MK1006 in Period 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK1006</intervention_name>
    <description>MK1006 capsules: 1 mg, 10 mg, and 20 mg.
Panel A: MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg
Panel B: MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.
Panel C: MK1006 capsules in five doses beginning at 140 mg and rising to 260 mg.
There will a 7-day interval between each dose</description>
    <arm_group_label>15 mg MK1006/Placebo/45 mg MK1006/60 mg MK1006/Placebo (Fed)</arm_group_label>
    <arm_group_label>Placebo/30mg MK1006/45mg MK1006/60mg MK1006/30mg MK1006 (Fed)</arm_group_label>
    <arm_group_label>15mg MK1006/30mg MK1006/Placebo/60mg MK1006/30mg MK1006 (Fed)</arm_group_label>
    <arm_group_label>15mg MK1006/30mg MK1006/45mg MK1006/Placebo/30mg MK1006 (Fed)</arm_group_label>
    <arm_group_label>60mg MK1006 / Placebo / 100mg MK1006 / 120mg MK1006 / Placebo</arm_group_label>
    <arm_group_label>Placebo/ 80mg MK1006/ 100mg MK1006/ 120mg MK1006/ 140mg MK1006</arm_group_label>
    <arm_group_label>60mg MK1006/ 80mg MK1006/ Placebo/ 120mg MK1006/ 140mg MK1006</arm_group_label>
    <arm_group_label>60mg MK1006/ 80mg MK1006/ 100mg MK1006/ Placebo/ 140mg MK1006</arm_group_label>
    <arm_group_label>140mg MK1006 / Placebo / 200mg MK1006 / 230mg MK1006 / Placebo</arm_group_label>
    <arm_group_label>Placebo/170mg MK1006/ 200mg MK1006/ 230mg MK1006/ 260mg MK1006</arm_group_label>
    <arm_group_label>140mg MK1006/170mg MK1006/ Placebo/ 230mg MK1006/ 260mg MK1006</arm_group_label>
    <arm_group_label>140mg MK1006/170mg MK1006/ 200mg MK1006/ Placebo/ 260mg MK1006</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule to match MK1006 1, 10, and 20 mg.
Panel A: Placebo to MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg
Panel B: Placebo to MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.
Panel C: Placebo to MK1006 capsules in 5 doses beginning at 140 mg and rising to 260 mg.
There will a 7-day interval between each dose</description>
    <arm_group_label>15 mg MK1006/Placebo/45 mg MK1006/60 mg MK1006/Placebo (Fed)</arm_group_label>
    <arm_group_label>Placebo/30mg MK1006/45mg MK1006/60mg MK1006/30mg MK1006 (Fed)</arm_group_label>
    <arm_group_label>15mg MK1006/30mg MK1006/Placebo/60mg MK1006/30mg MK1006 (Fed)</arm_group_label>
    <arm_group_label>15mg MK1006/30mg MK1006/45mg MK1006/Placebo/30mg MK1006 (Fed)</arm_group_label>
    <arm_group_label>60mg MK1006 / Placebo / 100mg MK1006 / 120mg MK1006 / Placebo</arm_group_label>
    <arm_group_label>Placebo/ 80mg MK1006/ 100mg MK1006/ 120mg MK1006/ 140mg MK1006</arm_group_label>
    <arm_group_label>60mg MK1006/ 80mg MK1006/ Placebo/ 120mg MK1006/ 140mg MK1006</arm_group_label>
    <arm_group_label>60mg MK1006/ 80mg MK1006/ 100mg MK1006/ Placebo/ 140mg MK1006</arm_group_label>
    <arm_group_label>140mg MK1006 / Placebo / 200mg MK1006 / 230mg MK1006 / Placebo</arm_group_label>
    <arm_group_label>Placebo/170mg MK1006/ 200mg MK1006/ 230mg MK1006/ 260mg MK1006</arm_group_label>
    <arm_group_label>140mg MK1006/170mg MK1006/ Placebo/ 230mg MK1006/ 260mg MK1006</arm_group_label>
    <arm_group_label>140mg MK1006/170mg MK1006/ 200mg MK1006/ Placebo/ 260mg MK1006</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is between 18 and 55 years of age. Participants up to 65 years of age may
             be enrolled in Panels B and C

          -  Female participants must be postmenopausal or otherwise unable to have children

          -  Participant has a body mass index (BMI) less than or equal to 42 kg/m^2 at the
             screening visit

          -  Participant has type 2 diabetes and is being treated with either diet and exercise or
             a single oral anti-hyperglycemic medication. For Panels B and C, participant may be
             treated with combination oral anti-hyperglycemic medications

          -  Participant is willing to follow the American Heart Association (AHA) diet and
             exercise program throughout the study

          -  Participant is a nonsmoker or has not used nicotine-containing products for 6 months
             prior to study start

        Exclusion Criteria:

          -  Participant has a history of stroke, seizures, or other neurological disorders

          -  Participant has a recent history of eye infection or other inflammatory eye conditions

          -  Participant has glaucoma or is blind

          -  Participant has had eye surgery within 6 months of study start (Lasik is permitted)

          -  Participant has type 1 diabetes

          -  Participant cannot stop taking any of their current prescription or non-prescription
             medications during the study

          -  Participant consumes more than 3 alcoholic beverages per day

          -  Participant consumes more than 6 caffeinated beverages per day

          -  Participant has had major surgery or has donated blood within 4 weeks of study start

          -  Participant has multiple and/or severe allergies to drugs or food
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2008</study_first_submitted>
  <study_first_submitted_qc>September 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2008</study_first_posted>
  <results_first_submitted>July 31, 2012</results_first_submitted>
  <results_first_submitted_qc>August 8, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 7, 2012</results_first_posted>
  <last_update_submitted>February 4, 2016</last_update_submitted>
  <last_update_submitted_qc>February 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>15mg MK1006/Placebo/45mg MK1006/60mg MK1006/Placebo (Fed)</title>
          <description>Participants received 15 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by placebo to MK1006 taken with food (Fed state) in Period 5.</description>
        </group>
        <group group_id="P2">
          <title>Placebo/30mg MK1006/45mg MK1006/60mg MK1006/30mg MK1006 (Fed)</title>
          <description>Participants received placebo to MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.</description>
        </group>
        <group group_id="P3">
          <title>15mg MK1006/30mg MK1006/Placebo/60mg MK1006/30mg MK1006 (Fed)</title>
          <description>Participants received 15 mg MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.</description>
        </group>
        <group group_id="P4">
          <title>15mg MK1006/30mg MK1006/45mg MK1006/Placebo/30mg MK1006 (Fed)</title>
          <description>Participants received 15 mg MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.</description>
        </group>
        <group group_id="P5">
          <title>60mg MK1006 / Placebo / 100mg MK1006 / 120mg MK1006 / Placebo</title>
          <description>Participants received 60 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by placebo to MK1006 in Period 5.</description>
        </group>
        <group group_id="P6">
          <title>Placebo/80mg MK1006/100mg MK1006/120mg MK1006/140mg MK1006</title>
          <description>Participants received placebo to MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by 140 mg MK1006 in Period 5.</description>
        </group>
        <group group_id="P7">
          <title>60mg MK1006/80mg MK1006/Placebo/120mg MK1006/140mg MK1006</title>
          <description>Participants received 60 mg MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by 140 mg MK1006 in Period 5.</description>
        </group>
        <group group_id="P8">
          <title>60 mg MK1006/80 mg MK1006/100 mg MK1006/Placebo/140 mg MK1006</title>
          <description>Participants received 60 mg MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 140 mg MK1006 in Period 5.</description>
        </group>
        <group group_id="P9">
          <title>140mg MK1006 / Placebo / 200mg MK1006 / 230mg MK1006 / Placebo</title>
          <description>Participants received 140 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by placebo to MK1006 in Period 5</description>
        </group>
        <group group_id="P10">
          <title>Placebo/170mg MK1006/200mg MK1006/230mg MK1006/260mg MK1006</title>
          <description>Participants received placebo to MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by 260 mg MK1006 in Period 5.</description>
        </group>
        <group group_id="P11">
          <title>140mg MK1006/170mg MK1006/Placebo/230mg MK1006/260mg MK1006</title>
          <description>Participants received 140 mg MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by 260 mg MK1006 in Period 5.</description>
        </group>
        <group group_id="P12">
          <title>140mg MK1006/170mg MK1006/200mg MK1006/Placebo/260mg MK1006</title>
          <description>Participants received 140 mg MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 260 mg MK1006 in Period 5.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2">One participant discontinued the study after Period 2 and was replaced by another participant.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1">One participant discontinued after receiving the 230 mg dose of MK1006 and was not replaced</participants>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1">Replacement participant discontinued after receiving placebo to 230mg MK1006 and was not replaced</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Participants were treated with MK1006 or dose-matched placebo over 5 treatment periods.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.2" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Adverse Events (AEs) On Study</title>
        <description>An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the treatment, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the treatment, was also considered an adverse experience.</description>
        <time_frame>From the time of the run-in period prior to the first dose of study drug through the end of the poststudy period (up to 3 weeks)</time_frame>
        <population>All Participants as Treated (APaT) Population; All participants who received at least one dose of the investigational drug.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 15 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O2">
            <title>30 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 30 mg MK1006 after an overnight fast</description>
          </group>
          <group group_id="O3">
            <title>45 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 45 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O4">
            <title>60 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 60 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O5">
            <title>80 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 80 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O6">
            <title>100 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 100 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O7">
            <title>120 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 120 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O8">
            <title>140 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 140 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O9">
            <title>170 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 170 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O10">
            <title>200 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 200 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O11">
            <title>230 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 230 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O12">
            <title>260 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 260 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O13">
            <title>30 mg MK1006 [Fed State]</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 30 mg MK1006 after a light breakfast.</description>
          </group>
          <group group_id="O14">
            <title>Placebo</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of dose-matched placebo to MK1006.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events (AEs) On Study</title>
          <description>An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the treatment, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the treatment, was also considered an adverse experience.</description>
          <population>All Participants as Treated (APaT) Population; All participants who received at least one dose of the investigational drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006</title>
        <description>The AUC(0-∞) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity.</description>
        <time_frame>From pre-dose to 168 hours post-dose</time_frame>
        <population>Per-Protocol (PP) Population; The subset of participants who complied with the protocol sufficiently to ensure that data was likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance included exposure to treatment, availability of measurements and absence of major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 15 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O2">
            <title>30 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 30 mg MK1006 after an overnight fast</description>
          </group>
          <group group_id="O3">
            <title>45 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 45 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O4">
            <title>60 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 60 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O5">
            <title>80 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 80 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O6">
            <title>100 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 100 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O7">
            <title>120 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 120 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O8">
            <title>140 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 140 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O9">
            <title>170 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 170 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O10">
            <title>200 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 200 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O11">
            <title>230 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 230 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O12">
            <title>260 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 260 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O13">
            <title>30 mg MK1006 [Fed State]</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 30 mg MK1006 after a light breakfast.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC[0-∞]) After Single Dose MK1006</title>
          <description>The AUC(0-∞) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity.</description>
          <population>Per-Protocol (PP) Population; The subset of participants who complied with the protocol sufficiently to ensure that data was likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance included exposure to treatment, availability of measurements and absence of major protocol violations.</population>
          <units>nM.hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="595" spread="106"/>
                    <measurement group_id="O2" value="1330" spread="193"/>
                    <measurement group_id="O3" value="1900" spread="464"/>
                    <measurement group_id="O4" value="2790" spread="810"/>
                    <measurement group_id="O5" value="4380" spread="1960"/>
                    <measurement group_id="O6" value="6360" spread="2680"/>
                    <measurement group_id="O7" value="7670" spread="1900"/>
                    <measurement group_id="O8" value="7500" spread="2800"/>
                    <measurement group_id="O9" value="8160" spread="3570"/>
                    <measurement group_id="O10" value="8440" spread="5520"/>
                    <measurement group_id="O11" value="11670" spread="4020"/>
                    <measurement group_id="O12" value="11460" spread="5340"/>
                    <measurement group_id="O13" value="1380" spread="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>A linear mixed-effect model was used to estimate the geometric mean AUC (0-∞) for MK1006 at every dose level.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess the effect of food at the 30 mg dose, a point estimate was constructed for the geometric mean ratio for the fed/fasted states (GMR[fed/fasted]) of MK1006 AUC (0-∞).
The GMR (fed/fasted) was calculated using the geometric mean AUC (0-∞) of the fed state divided by the geometric mean AUC (0-∞) fasted state.
A GMR (fed/fasted) point estimate value within 20% of unity (1.00) was considered consistent with an absence of a clinically significant food effect.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio (fed/fasted)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose</title>
        <time_frame>From pre-dose to 168 hours post-dose</time_frame>
        <population>Per-Protocol (PP) Population; The subset of participants who complied with the protocol sufficiently to ensure that data was likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance included exposure to treatment, availability of measurements and absence of major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 15 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O2">
            <title>30 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 30 mg MK1006 after an overnight fast</description>
          </group>
          <group group_id="O3">
            <title>45 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 45 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O4">
            <title>60 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 60 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O5">
            <title>80 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 80 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O6">
            <title>100 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 100 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O7">
            <title>120 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 120 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O8">
            <title>140 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 140 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O9">
            <title>170 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 170 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O10">
            <title>200 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 200 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O11">
            <title>230 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 230 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O12">
            <title>260 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 260 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O13">
            <title>30 mg MK1006 [Fed State]</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 30 mg MK1006 after a light breakfast.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Maximum Plasma Concentration (Cmax) of MK1006 After Single Dose</title>
          <population>Per-Protocol (PP) Population; The subset of participants who complied with the protocol sufficiently to ensure that data was likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance included exposure to treatment, availability of measurements and absence of major protocol violations.</population>
          <units>nM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" spread="22.7"/>
                    <measurement group_id="O2" value="123.0" spread="27.7"/>
                    <measurement group_id="O3" value="191.0" spread="76.5"/>
                    <measurement group_id="O4" value="251.0" spread="73.4"/>
                    <measurement group_id="O5" value="434.0" spread="196.0"/>
                    <measurement group_id="O6" value="614.0" spread="267.0"/>
                    <measurement group_id="O7" value="783.0" spread="230.0"/>
                    <measurement group_id="O8" value="786.0" spread="422."/>
                    <measurement group_id="O9" value="768.0" spread="364.0"/>
                    <measurement group_id="O10" value="738.0" spread="688.0"/>
                    <measurement group_id="O11" value="1174.0" spread="822.0"/>
                    <measurement group_id="O12" value="901.0" spread="508.0"/>
                    <measurement group_id="O13" value="141.0" spread="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>A linear mixed-effect model was used to estimate the geometric mean Cmax for MK1006 at every dose level.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To assess the effect of food at the 30 mg dose, a point estimate was constructed for the geometric mean ratio for the fed/fasted states (GMR[fed/fasted]) of MK1006 Cmax.
The GMR (fed/fasted) was calculated using the geometric mean Cmax of the fed state divided by the geometric mean Cmax fasted state.
A GMR (fed/fasted) point estimate value within 20% of unity (1.00) was considered consistent with an absence of a clinically significant food effect.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio (fed/fasted)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose</title>
        <time_frame>From pre-dose to 168 hours post-dose</time_frame>
        <population>Per-Protocol (PP) Population; The subset of participants who complied with the protocol sufficiently to ensure that data was likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance included exposure to treatment, availability of measurements and absence of major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 15 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O2">
            <title>30 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 30 mg MK1006 after an overnight fast</description>
          </group>
          <group group_id="O3">
            <title>45 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 45 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O4">
            <title>60 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 60 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O5">
            <title>80 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 80 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O6">
            <title>100 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 100 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O7">
            <title>120 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 120 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O8">
            <title>140 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 140 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O9">
            <title>170 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 170 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O10">
            <title>200 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 200 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O11">
            <title>230 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 230 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O12">
            <title>260 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 260 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O13">
            <title>30 mg MK1006 [Fed State]</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 30 mg MK1006 after a light breakfast.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time of Maximum Plasma Concentration (Tmax) of MK1006 After Single Dose</title>
          <population>Per-Protocol (PP) Population; The subset of participants who complied with the protocol sufficiently to ensure that data was likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance included exposure to treatment, availability of measurements and absence of major protocol violations.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="2.0" upper_limit="5.0"/>
                    <measurement group_id="O4" value="3.0" lower_limit="3.0" upper_limit="5.0"/>
                    <measurement group_id="O5" value="3.0" lower_limit="2.0" upper_limit="5.0"/>
                    <measurement group_id="O6" value="3.0" lower_limit="2.0" upper_limit="5.0"/>
                    <measurement group_id="O7" value="4.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O8" value="3.0" lower_limit="2.0" upper_limit="5.0"/>
                    <measurement group_id="O9" value="3.5" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O10" value="5.0" lower_limit="2.0" upper_limit="5.0"/>
                    <measurement group_id="O11" value="4.0" lower_limit="2.0" upper_limit="5.0"/>
                    <measurement group_id="O12" value="4.5" lower_limit="4.0" upper_limit="5.0"/>
                    <measurement group_id="O13" value="2.0" lower_limit="2.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose</title>
        <description>The apparent terminal half-life was defined as the time required for the plasma concentration of MK1006 to decrease 50% in the final stage of its elimination</description>
        <time_frame>From pre-dose to 168 hours post-dose</time_frame>
        <population>Per-Protocol (PP) Population; The subset of participants who complied with the protocol sufficiently to ensure that data was likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance included exposure to treatment, availability of measurements and absence of major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 15 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O2">
            <title>30 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 30 mg MK1006 after an overnight fast</description>
          </group>
          <group group_id="O3">
            <title>45 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 45 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O4">
            <title>60 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 60 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O5">
            <title>80 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 80 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O6">
            <title>100 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 100 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O7">
            <title>120 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 120 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O8">
            <title>140 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 140 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O9">
            <title>170 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 170 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O10">
            <title>200 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 200 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O11">
            <title>230 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 230 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O12">
            <title>260 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 260 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O13">
            <title>30 mg MK1006 [Fed State]</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 30 mg MK1006 after a light breakfast.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-Life (T 1/2) of MK1006 After Single Dose</title>
          <description>The apparent terminal half-life was defined as the time required for the plasma concentration of MK1006 to decrease 50% in the final stage of its elimination</description>
          <population>Per-Protocol (PP) Population; The subset of participants who complied with the protocol sufficiently to ensure that data was likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance included exposure to treatment, availability of measurements and absence of major protocol violations.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" spread="3.1"/>
                    <measurement group_id="O2" value="17.3" spread="1.3"/>
                    <measurement group_id="O3" value="17.6" spread="3.5"/>
                    <measurement group_id="O4" value="18.3" spread="2.3"/>
                    <measurement group_id="O5" value="20.0" spread="1.4"/>
                    <measurement group_id="O6" value="23.0" spread="5.2"/>
                    <measurement group_id="O7" value="19.3" spread="4.7"/>
                    <measurement group_id="O8" value="25.7" spread="5.6"/>
                    <measurement group_id="O9" value="22.3" spread="5.6"/>
                    <measurement group_id="O10" value="22.8" spread="5.0"/>
                    <measurement group_id="O11" value="26.7" spread="2.6"/>
                    <measurement group_id="O12" value="31.3" spread="6.6"/>
                    <measurement group_id="O13" value="19.2" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued Treatment Due to an AE</title>
        <description>An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the treatment, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the treatment, was also considered an adverse experience.</description>
        <time_frame>From the time of the run-in period prior to the first dose of study drug through the end of the poststudy period (up to 3 weeks)</time_frame>
        <population>All Participants as Treated (APaT) Population; All participants who received at least one dose of the investigational drug.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 15 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O2">
            <title>30 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 30 mg MK1006 after an overnight fast</description>
          </group>
          <group group_id="O3">
            <title>45 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 45 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O4">
            <title>60 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 60 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O5">
            <title>80 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 80 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O6">
            <title>100 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 100 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O7">
            <title>120 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 120 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O8">
            <title>140 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 140 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O9">
            <title>170 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 170 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O10">
            <title>200 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 200 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O11">
            <title>230 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 230 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O12">
            <title>260 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 260 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O13">
            <title>30 mg MK1006 [Fed State]</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 30 mg MK1006 after a light breakfast.</description>
          </group>
          <group group_id="O14">
            <title>Placebo</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of dose-matched placebo to MK1006.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Treatment Due to an AE</title>
          <description>An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the treatment, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the treatment, was also considered an adverse experience.</description>
          <population>All Participants as Treated (APaT) Population; All participants who received at least one dose of the investigational drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="6"/>
                <count group_id="O14" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006</title>
        <description>The AUC(0-24) was estimated by determining the total area under the curve of the concentration versus time curve to 24 hours post dose.</description>
        <time_frame>From pre-dose to 168 hours post-dose</time_frame>
        <population>Per-Protocol (PP) Population; The subset of participants who complied with the protocol sufficiently to ensure that data was likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance included exposure to treatment, availability of measurements and absence of major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 15 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O2">
            <title>30 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 30 mg MK1006 after an overnight fast</description>
          </group>
          <group group_id="O3">
            <title>45 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 45 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O4">
            <title>60 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 60 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O5">
            <title>80 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 80 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O6">
            <title>100 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 100 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O7">
            <title>120 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 120 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O8">
            <title>140 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 140 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O9">
            <title>170 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 170 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O10">
            <title>200 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 200 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O11">
            <title>230 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 230 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O12">
            <title>260 mg MK1006</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 260 mg MK1006 after an overnight fast.</description>
          </group>
          <group group_id="O13">
            <title>30 mg MK1006 [Fed State]</title>
            <description>After a minimum washout period of 7 days, participants received a single dose of 30 mg MK1006 after a light breakfast.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Area Under The Plasma Concentration Curve From Time Zero to 24 Hours (AUC[0-24]) After Single Dose MK1006</title>
          <description>The AUC(0-24) was estimated by determining the total area under the curve of the concentration versus time curve to 24 hours post dose.</description>
          <population>Per-Protocol (PP) Population; The subset of participants who complied with the protocol sufficiently to ensure that data was likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance included exposure to treatment, availability of measurements and absence of major protocol violations.</population>
          <units>nM.hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="468" spread="101"/>
                    <measurement group_id="O2" value="1030" spread="155"/>
                    <measurement group_id="O3" value="1520" spread="416"/>
                    <measurement group_id="O4" value="2100" spread="580"/>
                    <measurement group_id="O5" value="3450" spread="1570"/>
                    <measurement group_id="O6" value="4930" spread="2120"/>
                    <measurement group_id="O7" value="6110" spread="1420"/>
                    <measurement group_id="O8" value="5690" spread="2490"/>
                    <measurement group_id="O9" value="6590" spread="3320"/>
                    <measurement group_id="O10" value="6270" spread="4850"/>
                    <measurement group_id="O11" value="8810" spread="3780"/>
                    <measurement group_id="O12" value="8500" spread="4380"/>
                    <measurement group_id="O13" value="1060" spread="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of the run-in period prior to the first dose of study drug through the end of the poststudy period (up to 3 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>15 mg MK1006</title>
          <description>After a minimum washout period of 7 days, participants received a single dose of 15 mg MK1006 after an overnight fast.</description>
        </group>
        <group group_id="E2">
          <title>30 mg MK1006</title>
          <description>After a minimum washout period of 7 days, participants received a single dose of 30 mg MK1006 after an overnight fast</description>
        </group>
        <group group_id="E3">
          <title>45 mg MK1006</title>
          <description>After a minimum washout period of 7 days, participants received a single dose of 45 mg MK1006 after an overnight fast.</description>
        </group>
        <group group_id="E4">
          <title>60 mg MK1006</title>
          <description>After a minimum washout period of 7 days, participants received a single dose of 60 mg MK1006 after an overnight fast.</description>
        </group>
        <group group_id="E5">
          <title>80 mg MK1006</title>
          <description>After a minimum washout period of 7 days, participants received a single dose of 80 mg MK1006 after an overnight fast.</description>
        </group>
        <group group_id="E6">
          <title>100 mg MK1006</title>
          <description>After a minimum washout period of 7 days, participants received a single dose of 100 mg MK1006 after an overnight fast.</description>
        </group>
        <group group_id="E7">
          <title>120 mg MK1006</title>
          <description>After a minimum washout period of 7 days, participants received a single dose of 120 mg MK1006 after an overnight fast.</description>
        </group>
        <group group_id="E8">
          <title>140 mg MK1006</title>
          <description>After a minimum washout period of 7 days, participants received a single dose of 140 mg MK1006 after an overnight fast.</description>
        </group>
        <group group_id="E9">
          <title>170 mg MK1006</title>
          <description>After a minimum washout period of 7 days, participants received a single dose of 170 mg MK1006 after an overnight fast.</description>
        </group>
        <group group_id="E10">
          <title>200 mg MK1006</title>
          <description>After a minimum washout period of 7 days, participants received a single dose of 200 mg MK1006 after an overnight fast.</description>
        </group>
        <group group_id="E11">
          <title>230 mg MK1006</title>
          <description>After a minimum washout period of 7 days, participants received a single dose of 230 mg MK1006 after an overnight fast.</description>
        </group>
        <group group_id="E12">
          <title>260 mg MK1006</title>
          <description>After a minimum washout period of 7 days, participants received a single dose of 260 mg MK1006 after an overnight fast.</description>
        </group>
        <group group_id="E13">
          <title>30 mg MK1006 [Fed State]</title>
          <description>After a minimum washout period of 7 days, participants received a single dose of 30 mg MK1006 after a light breakfast.</description>
        </group>
        <group group_id="E14">
          <title>Placebo</title>
          <description>After a minimum washout period of 7 days, participants received a single dose of dose-matched placebo to MK1006.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="12" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo Positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Eye Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ocular Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pterygium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Feeling Hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infusion Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis Externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-Reactive Protein Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T Wave Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ingrown Hair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Night Sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

